纤维蛋白原在肝硬化和肝细胞癌患者血浆中的含量分析

Analysis of plasma fibrinogen content in liver cirrhosis and hepatocellular carcinoma*

目的探讨肝硬化(livercirrhosis,LC)和肝细胞癌(hepatocellularcarcinoma,HCC)患者血浆纤维蛋白原(fibrinogen,FG)含量与临床分期的关系。方法采用凝固比浊法对40例LC和57例HCC的血浆FG加以检测。结果与正常对照组(2.90±0.46)mg/L相比,LC组的血浆FG含量明显降低(1.81±0.83)mg/L,(P<0.01),其中肝功能代偿期为(1.89±0.34)mg/L,失代偿期为(1.53±0.26)mg/L,二者之间具有显著性差别(P<0.05)。相反HCC组的血浆FG含量(3.75±1.41)mg/L则显著高于正常对照组(P<0.01),并且随肿瘤不同分期(Ⅰ、Ⅱ、Ⅲ)呈递增趋势。结论血浆FG含量异常与LC和HCC的临床分期密切相关,可作为评估患者病情和结局的重要生化指标。

[Objective] To investigate the relationship between plasma fibrinogen content and clinical stage of liver cirrhosis （LC） and hepatocellular carcinoma （HCC）. [Methods] The plasma fibrinogen content of 40 patients with LC and 57 patients with HCC was examined by using von Clauss method. [Results] The plasma fibrinogen content significantly decreased in 40 cirrhotic patients （1.81±0.83） mg/L compared with normal control （2.90±0.46） mg/L （P 〈0.01）, and there was distinct difference between the compensated stage （1.89±0.34） mg/L and decompensated stage （1.53±0.26） mg/L （P 〈0.05）. On the contrary, the plasma fibrinogen content was significantly higher in 57 HCC patients （3.75±1.41） mg/L than in normal control （P 〈0.01）. Moreover, the plasma fibrinogen content increased progressively accompanying with tumor＇s different stages （ Ⅰ , Ⅱ, Ⅲ） in HCC group. [ Conclusion] The abnormality of plasma fib,＇inogen content has close relationship with clinical stage of LC and HCC, which indicates that plasma fibfinogen may serve as an important biochemical parameter for evaluating patient＇s condition and outcome.